Alligator Bioscience completes patient enrollment for 600 mg dose cohort phase I trial of ATOR-1017 to treat advanced/metastatic cancer
By, Admin1 min read
Share
Alligator Bioscience, a clinical-stage biotechnology company, announced the completion of the patient enrollment for the 600 mg dose cohort from Alligator
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
